UY30334A1 - Derivados de triazolopirazina - Google Patents

Derivados de triazolopirazina

Info

Publication number
UY30334A1
UY30334A1 UY30334A UY30334A UY30334A1 UY 30334 A1 UY30334 A1 UY 30334A1 UY 30334 A UY30334 A UY 30334A UY 30334 A UY30334 A UY 30334A UY 30334 A1 UY30334 A1 UY 30334A1
Authority
UY
Uruguay
Prior art keywords
triazolopirazine
derivatives
compounds
formula
relates
Prior art date
Application number
UY30334A
Other languages
English (en)
Inventor
Mitchell David Nambu
Phuong Thi Quy Le
Mary Catherine Johnson
Jacqui Elizabeth Hoffman
Jingrong Jean Cui
Michelle Bich Tran-Dube
Hong Shen
Mason Alan Pairish
Lei Jia
Hengmiao Cheng
Robert Steven Kania
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY30334A1 publication Critical patent/UY30334A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invencion se refiere a compuestos de formula I o una sal farmacéuticamente aceptable de los mismos, en la que R1, R2, R3 y R4 son como se definen en esta invencion. La invencion también se refiere a composiciones farmacéuticas que contienen los compuestos de formula I y a procedimientos de tratamiento de trastornos hiperproliferativos en un mamífero mediante administracion de los compuestos de formula I.
UY30334A 2006-05-11 2007-05-09 Derivados de triazolopirazina UY30334A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79996606P 2006-05-11 2006-05-11
US89323107P 2007-03-06 2007-03-06

Publications (1)

Publication Number Publication Date
UY30334A1 true UY30334A1 (es) 2008-01-02

Family

ID=38441445

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30334A UY30334A1 (es) 2006-05-11 2007-05-09 Derivados de triazolopirazina

Country Status (32)

Country Link
US (2) US7732604B2 (es)
EP (1) EP2018383B1 (es)
JP (1) JP4377962B2 (es)
KR (1) KR101099161B1 (es)
CN (1) CN101443331A (es)
AP (1) AP2008004674A0 (es)
AR (1) AR060994A1 (es)
AT (1) ATE532785T1 (es)
AU (1) AU2007251283A1 (es)
BR (1) BRPI0711809A2 (es)
CA (1) CA2651363C (es)
CR (1) CR10383A (es)
EA (1) EA016204B1 (es)
EC (1) ECSP088871A (es)
ES (1) ES2376913T3 (es)
GE (1) GEP20115174B (es)
GT (1) GT200700039A (es)
HN (1) HN2007015177A (es)
IL (1) IL194813A0 (es)
MA (1) MA30411B1 (es)
ME (1) MEP36508A (es)
MX (1) MX2008014399A (es)
NL (1) NL2000613C2 (es)
NO (1) NO20085060L (es)
NZ (1) NZ572361A (es)
PE (1) PE20080067A1 (es)
RS (1) RS20080533A (es)
TN (1) TNSN08445A1 (es)
TW (1) TWI346115B (es)
UY (1) UY30334A1 (es)
WO (1) WO2007132308A1 (es)
ZA (1) ZA200809020B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
JPWO2009107391A1 (ja) * 2008-02-27 2011-06-30 武田薬品工業株式会社 ６員芳香環含有化合物
KR20100128305A (ko) * 2008-02-28 2010-12-07 노파르티스 아게 Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체
WO2009111354A2 (en) * 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
WO2009157196A1 (ja) * 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
WO2010068292A1 (en) * 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
MX2011006682A (es) 2008-12-22 2011-07-13 Merck Patent Gmbh Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010138665A1 (en) * 2009-05-28 2010-12-02 Vertex Pharmaceuticals Incorporated Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
DE102009056886A1 (de) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
PE20160588A1 (es) * 2009-12-31 2016-07-09 Hutchison Medipharma Ltd Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
TWI423974B (zh) * 2010-02-11 2014-01-21 Hutchison Medipharma Ltd 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
JP2013526570A (ja) 2010-05-14 2013-06-24 オーエスアイ・ファーマシューティカルズ，エルエルシー 縮合二環式キナーゼ阻害剤
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN103204844A (zh) * 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
NZ629499A (en) 2012-03-30 2016-05-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
IN2014DN07410A (es) 2012-04-03 2015-04-24 Novartis Ag
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
CN107312009B (zh) * 2013-04-17 2022-09-20 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
DK3053923T3 (en) 2013-09-30 2018-07-23 Korea Res Inst Chemical Tech TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP2018123059A (ja) * 2015-06-10 2018-08-09 石原産業株式会社 １−シクロプロピルエチルアミン又はその塩の製造方法
CN107922396B (zh) * 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
US10301325B2 (en) 2015-09-24 2019-05-28 Shanghai Haiju Biological Technology Co., Ltd. Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
CN106928233B (zh) * 2015-12-31 2021-02-12 上海医药集团股份有限公司 喹啉类化合物的盐，其晶型、制备方法、组合物与应用
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
BR112018076443A2 (pt) * 2016-06-20 2019-04-09 Novartis Ag formas cristalinas de um composto de triazolopirimidina
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
CN108276418A (zh) * 2018-03-20 2018-07-13 北京凯恩梅格医药科技有限公司 化合物、含有该化合物的药用组合物及其用途
MX2021006982A (es) * 2018-12-14 2021-09-10 Beta Pharma Inc Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos.
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AU3766897A (en) 1996-07-13 1998-02-09 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
BR9710362A (pt) 1996-07-13 1999-08-17 Glaxo Group Ltd Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CA2385747A1 (en) * 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
US7250417B2 (en) * 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
CA2537916A1 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US10181126B2 (en) 2012-03-13 2019-01-15 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
TNSN08445A1 (fr) 2010-04-14
NL2000613C2 (nl) 2007-11-20
BRPI0711809A2 (pt) 2011-12-06
TW200804384A (en) 2008-01-16
TWI346115B (en) 2011-08-01
GEP20115174B (en) 2011-03-10
CR10383A (es) 2008-11-11
US20100105656A1 (en) 2010-04-29
KR20090006187A (ko) 2009-01-14
AR060994A1 (es) 2008-07-30
ES2376913T3 (es) 2012-03-20
HN2007015177A (es) 2010-06-09
RS20080533A (en) 2009-09-08
IL194813A0 (en) 2009-08-03
MEP36508A (en) 2011-02-10
NZ572361A (en) 2012-02-24
CA2651363C (en) 2011-07-12
GT200700039A (es) 2008-06-02
EA016204B1 (ru) 2012-03-30
EP2018383B1 (en) 2011-11-09
US20070265272A1 (en) 2007-11-15
WO2007132308A1 (en) 2007-11-22
NO20085060L (no) 2008-12-03
AP2008004674A0 (en) 2008-12-31
MA30411B1 (fr) 2009-05-04
CA2651363A1 (en) 2007-11-22
AU2007251283A1 (en) 2007-11-22
US7732604B2 (en) 2010-06-08
ZA200809020B (en) 2009-12-30
ATE532785T1 (de) 2011-11-15
ECSP088871A (es) 2008-12-30
EP2018383A1 (en) 2009-01-28
CN101443331A (zh) 2009-05-27
KR101099161B1 (ko) 2011-12-27
EA200870423A1 (ru) 2009-04-28
JP4377962B2 (ja) 2009-12-02
JP2009536636A (ja) 2009-10-15
PE20080067A1 (es) 2008-03-10
MX2008014399A (es) 2008-11-27

Similar Documents

Publication Publication Date Title
UY30334A1 (es) Derivados de triazolopirazina
ECSP055867A (es) Derivados de pirrolopirimidina
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
CR10027A (es) Nuevos derivados de pirrol fusionado
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
CR11568A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis
TR201906123T4 (tr) P13 kinazı ve mtor inhibitörleri olarak triazin bileşikleri.
WO2007138472A3 (en) Triazolopyridazine derivatives
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
UY30500A1 (es) Compuestos de azabencimidazolilo
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
GEP20125487B (en) Organic compounds and their use
GT200600518A (es) Derivados de pirimidina
ECSP099177A (es) Derivados de quinazolinona e isoquinolinona
CR10327A (es) "PIRIDIN(3-4-b) PIRAZINONAS"
DK2074120T3 (da) Tropan-forbindelser
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
TW200626158A (en) Naphthaline derivatives
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
TW200637817A (en) 5-aminoindole derivatives
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY